ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Platinum-based Antineoplastic Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-39F12501
Home | Market Reports | Health| Health Conditions| Cancer
Global Platinum based Antineoplastic Market Research Report 2022
BUY CHAPTERS

Global Platinum-based Antineoplastic Market Research Report 2025

Code: QYRE-Auto-39F12501
Report
March 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Astrazeneca plc
Roche
Sanofi
Bristol–Myers Squibb
Simcere Pharmaceutical
AbbVie
Novartis
GSK
MSD
Hengrui Medicine
CSPC Pharmaceutical Group
Asta Medica GmbH
Hansoh Pharmaceutical Group
ChiTaiTianQing Pharmaceutical Group

Platinum-based Antineoplastic Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Platinum-based Antineoplastic Market

Platinum-based Antineoplastic Market

The global market for Platinum-based Antineoplastic was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Platinum-based Antineoplastic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Platinum-based Antineoplastic.
The Platinum-based Antineoplastic market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Platinum-based Antineoplastic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Platinum-based Antineoplastic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Platinum-based Antineoplastic Market Report

Report Metric Details
Report Name Platinum-based Antineoplastic Market
CAGR 5%
Segment by Type
  • Cisplatin
  • Carboplatin
  • Nedaplatin
  • Oxaliplatin
  • Lobaplatin
  • Cycloplatin
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie, Novartis, GSK, MSD, Hengrui Medicine, Hansoh Pharmaceutical Group, ChiTaiTianQing Pharmaceutical Group, CSPC Pharmaceutical Group
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Platinum-based Antineoplastic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Platinum-based Antineoplastic Market report?

Ans: The main players in the Platinum-based Antineoplastic Market are Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie, Novartis, GSK, MSD, Hengrui Medicine, Hansoh Pharmaceutical Group, ChiTaiTianQing Pharmaceutical Group, CSPC Pharmaceutical Group

What are the Application segmentation covered in the Platinum-based Antineoplastic Market report?

Ans: The Applications covered in the Platinum-based Antineoplastic Market report are Combination Therapy, Monotherapy, Targeted Therapy

What are the Type segmentation covered in the Platinum-based Antineoplastic Market report?

Ans: The Types covered in the Platinum-based Antineoplastic Market report are Cisplatin, Carboplatin, Nedaplatin, Oxaliplatin, Lobaplatin, Cycloplatin

Recommended Reports

Cancer Therapeutics

Oncology Diagnostics

Chemotherapy Drugs

1 Platinum-based Antineoplastic Market Overview
1.1 Product Definition
1.2 Platinum-based Antineoplastic by Type
1.2.1 Global Platinum-based Antineoplastic Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cisplatin
1.2.3 Carboplatin
1.2.4 Nedaplatin
1.2.5 Oxaliplatin
1.2.6 Lobaplatin
1.2.7 Cycloplatin
1.3 Platinum-based Antineoplastic by Application
1.3.1 Global Platinum-based Antineoplastic Market Value by Application (2024 VS 2031)
1.3.2 Combination Therapy
1.3.3 Monotherapy
1.3.4 Targeted Therapy
1.4 Global Platinum-based Antineoplastic Market Size Estimates and Forecasts
1.4.1 Global Platinum-based Antineoplastic Revenue 2020-2031
1.4.2 Global Platinum-based Antineoplastic Sales 2020-2031
1.4.3 Global Platinum-based Antineoplastic Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Platinum-based Antineoplastic Market Competition by Manufacturers
2.1 Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2020-2025)
2.2 Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Platinum-based Antineoplastic Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Platinum-based Antineoplastic, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application
2.7 Global Key Manufacturers of Platinum-based Antineoplastic, Date of Enter into This Industry
2.8 Global Platinum-based Antineoplastic Market Competitive Situation and Trends
2.8.1 Global Platinum-based Antineoplastic Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Platinum-based Antineoplastic Players Market Share by Revenue
2.8.3 Global Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Platinum-based Antineoplastic Market Scenario by Region
3.1 Global Platinum-based Antineoplastic Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Platinum-based Antineoplastic Sales by Region: 2020-2031
3.2.1 Global Platinum-based Antineoplastic Sales by Region: 2020-2025
3.2.2 Global Platinum-based Antineoplastic Sales by Region: 2026-2031
3.3 Global Platinum-based Antineoplastic Revenue by Region: 2020-2031
3.3.1 Global Platinum-based Antineoplastic Revenue by Region: 2020-2025
3.3.2 Global Platinum-based Antineoplastic Revenue by Region: 2026-2031
3.4 North America Platinum-based Antineoplastic Market Facts & Figures by Country
3.4.1 North America Platinum-based Antineoplastic Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Platinum-based Antineoplastic Sales by Country (2020-2031)
3.4.3 North America Platinum-based Antineoplastic Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Platinum-based Antineoplastic Market Facts & Figures by Country
3.5.1 Europe Platinum-based Antineoplastic Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Platinum-based Antineoplastic Sales by Country (2020-2031)
3.5.3 Europe Platinum-based Antineoplastic Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Platinum-based Antineoplastic Market Facts & Figures by Region
3.6.1 Asia Pacific Platinum-based Antineoplastic Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Platinum-based Antineoplastic Sales by Region (2020-2031)
3.6.3 Asia Pacific Platinum-based Antineoplastic Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Platinum-based Antineoplastic Market Facts & Figures by Country
3.7.1 Latin America Platinum-based Antineoplastic Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Platinum-based Antineoplastic Sales by Country (2020-2031)
3.7.3 Latin America Platinum-based Antineoplastic Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Platinum-based Antineoplastic Market Facts & Figures by Country
3.8.1 Middle East and Africa Platinum-based Antineoplastic Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Platinum-based Antineoplastic Sales by Country (2020-2031)
3.8.3 Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Platinum-based Antineoplastic Sales by Type (2020-2031)
4.1.1 Global Platinum-based Antineoplastic Sales by Type (2020-2025)
4.1.2 Global Platinum-based Antineoplastic Sales by Type (2026-2031)
4.1.3 Global Platinum-based Antineoplastic Sales Market Share by Type (2020-2031)
4.2 Global Platinum-based Antineoplastic Revenue by Type (2020-2031)
4.2.1 Global Platinum-based Antineoplastic Revenue by Type (2020-2025)
4.2.2 Global Platinum-based Antineoplastic Revenue by Type (2026-2031)
4.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Type (2020-2031)
4.3 Global Platinum-based Antineoplastic Price by Type (2020-2031)
5 Segment by Application
5.1 Global Platinum-based Antineoplastic Sales by Application (2020-2031)
5.1.1 Global Platinum-based Antineoplastic Sales by Application (2020-2025)
5.1.2 Global Platinum-based Antineoplastic Sales by Application (2026-2031)
5.1.3 Global Platinum-based Antineoplastic Sales Market Share by Application (2020-2031)
5.2 Global Platinum-based Antineoplastic Revenue by Application (2020-2031)
5.2.1 Global Platinum-based Antineoplastic Revenue by Application (2020-2025)
5.2.2 Global Platinum-based Antineoplastic Revenue by Application (2026-2031)
5.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Application (2020-2031)
5.3 Global Platinum-based Antineoplastic Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Platinum-based Antineoplastic Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche Platinum-based Antineoplastic Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Company Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Company Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Asta Medica GmbH
6.6.1 Asta Medica GmbH Company Information
6.6.2 Asta Medica GmbH Description and Business Overview
6.6.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
6.6.5 Asta Medica GmbH Recent Developments/Updates
6.7 Simcere Pharmaceutical
6.7.1 Simcere Pharmaceutical Company Information
6.7.2 Simcere Pharmaceutical Description and Business Overview
6.7.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
6.7.5 Simcere Pharmaceutical Recent Developments/Updates
6.8 Abbvie
6.8.1 Abbvie Company Information
6.8.2 Abbvie Description and Business Overview
6.8.3 Abbvie Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Abbvie Platinum-based Antineoplastic Product Portfolio
6.8.5 Abbvie Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Company Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novartis Platinum-based Antineoplastic Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 GSK
6.10.1 GSK Company Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.10.4 GSK Platinum-based Antineoplastic Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 MSD
6.11.1 MSD Company Information
6.11.2 MSD Description and Business Overview
6.11.3 MSD Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.11.4 MSD Platinum-based Antineoplastic Product Portfolio
6.11.5 MSD Recent Developments/Updates
6.12 Hengrui Medicine
6.12.1 Hengrui Medicine Company Information
6.12.2 Hengrui Medicine Description and Business Overview
6.12.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
6.12.5 Hengrui Medicine Recent Developments/Updates
6.13 Hansoh Pharmaceutical Group
6.13.1 Hansoh Pharmaceutical Group Company Information
6.13.2 Hansoh Pharmaceutical Group Description and Business Overview
6.13.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.13.5 Hansoh Pharmaceutical Group Recent Developments/Updates
6.14 ChiTaiTianQing Pharmaceutical Group
6.14.1 ChiTaiTianQing Pharmaceutical Group Company Information
6.14.2 ChiTaiTianQing Pharmaceutical Group Description and Business Overview
6.14.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.14.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.14.5 ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates
6.15 CSPC Pharmaceutical Group
6.15.1 CSPC Pharmaceutical Group Company Information
6.15.2 CSPC Pharmaceutical Group Description and Business Overview
6.15.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.15.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.15.5 CSPC Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Platinum-based Antineoplastic Industry Chain Analysis
7.2 Platinum-based Antineoplastic Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Platinum-based Antineoplastic Production Mode & Process Analysis
7.4 Platinum-based Antineoplastic Sales and Marketing
7.4.1 Platinum-based Antineoplastic Sales Channels
7.4.2 Platinum-based Antineoplastic Distributors
7.5 Platinum-based Antineoplastic Customer Analysis
8 Platinum-based Antineoplastic Market Dynamics
8.1 Platinum-based Antineoplastic Industry Trends
8.2 Platinum-based Antineoplastic Market Drivers
8.3 Platinum-based Antineoplastic Market Challenges
8.4 Platinum-based Antineoplastic Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Astrazeneca plc
Roche
Sanofi
Bristol–Myers Squibb
Simcere Pharmaceutical
AbbVie
Novartis
GSK
MSD
Hengrui Medicine
CSPC Pharmaceutical Group
Asta Medica GmbH
Hansoh Pharmaceutical Group
ChiTaiTianQing Pharmaceutical Group
List of Tables
 Table 1. Global Platinum-based Antineoplastic Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Platinum-based Antineoplastic Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Platinum-based Antineoplastic Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Platinum-based Antineoplastic Sales (Units) of Key Manufacturers (2020-2025)
 Table 5. Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Platinum-based Antineoplastic Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Platinum-based Antineoplastic Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Platinum-based Antineoplastic Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Platinum-based Antineoplastic, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application
 Table 12. Global Key Manufacturers of Platinum-based Antineoplastic, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Platinum-based Antineoplastic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum-based Antineoplastic as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Platinum-based Antineoplastic Sales by Region (2020-2025) & (Units)
 Table 18. Global Platinum-based Antineoplastic Sales Market Share by Region (2020-2025)
 Table 19. Global Platinum-based Antineoplastic Sales by Region (2026-2031) & (Units)
 Table 20. Global Platinum-based Antineoplastic Sales Market Share by Region (2026-2031)
 Table 21. Global Platinum-based Antineoplastic Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Platinum-based Antineoplastic Revenue Market Share by Region (2020-2025)
 Table 23. Global Platinum-based Antineoplastic Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Platinum-based Antineoplastic Revenue Market Share by Region (2026-2031)
 Table 25. North America Platinum-based Antineoplastic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Platinum-based Antineoplastic Sales by Country (2020-2025) & (Units)
 Table 27. North America Platinum-based Antineoplastic Sales by Country (2026-2031) & (Units)
 Table 28. North America Platinum-based Antineoplastic Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Platinum-based Antineoplastic Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Platinum-based Antineoplastic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Platinum-based Antineoplastic Sales by Country (2020-2025) & (Units)
 Table 32. Europe Platinum-based Antineoplastic Sales by Country (2026-2031) & (Units)
 Table 33. Europe Platinum-based Antineoplastic Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Platinum-based Antineoplastic Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Platinum-based Antineoplastic Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Platinum-based Antineoplastic Sales by Region (2020-2025) & (Units)
 Table 37. Asia Pacific Platinum-based Antineoplastic Sales by Region (2026-2031) & (Units)
 Table 38. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Platinum-based Antineoplastic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Platinum-based Antineoplastic Sales by Country (2020-2025) & (Units)
 Table 42. Latin America Platinum-based Antineoplastic Sales by Country (2026-2031) & (Units)
 Table 43. Latin America Platinum-based Antineoplastic Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Platinum-based Antineoplastic Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Platinum-based Antineoplastic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Platinum-based Antineoplastic Sales by Country (2020-2025) & (Units)
 Table 47. Middle East and Africa Platinum-based Antineoplastic Sales by Country (2026-2031) & (Units)
 Table 48. Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Platinum-based Antineoplastic Sales (Units) by Type (2020-2025)
 Table 51. Global Platinum-based Antineoplastic Sales (Units) by Type (2026-2031)
 Table 52. Global Platinum-based Antineoplastic Sales Market Share by Type (2020-2025)
 Table 53. Global Platinum-based Antineoplastic Sales Market Share by Type (2026-2031)
 Table 54. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Platinum-based Antineoplastic Revenue Market Share by Type (2020-2025)
 Table 57. Global Platinum-based Antineoplastic Revenue Market Share by Type (2026-2031)
 Table 58. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Platinum-based Antineoplastic Sales (Units) by Application (2020-2025)
 Table 61. Global Platinum-based Antineoplastic Sales (Units) by Application (2026-2031)
 Table 62. Global Platinum-based Antineoplastic Sales Market Share by Application (2020-2025)
 Table 63. Global Platinum-based Antineoplastic Sales Market Share by Application (2026-2031)
 Table 64. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Platinum-based Antineoplastic Revenue Market Share by Application (2020-2025)
 Table 67. Global Platinum-based Antineoplastic Revenue Market Share by Application (2026-2031)
 Table 68. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Platinum-based Antineoplastic Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. AstraZeneca Company Information
 Table 76. AstraZeneca Description and Business Overview
 Table 77. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. AstraZeneca Platinum-based Antineoplastic Product
 Table 79. AstraZeneca Recent Developments/Updates
 Table 80. Roche Company Information
 Table 81. Roche Description and Business Overview
 Table 82. Roche Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Roche Platinum-based Antineoplastic Product
 Table 84. Roche Recent Developments/Updates
 Table 85. Sanofi Company Information
 Table 86. Sanofi Description and Business Overview
 Table 87. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sanofi Platinum-based Antineoplastic Product
 Table 89. Sanofi Recent Developments/Updates
 Table 90. Bristol-Myers Squibb Company Information
 Table 91. Bristol-Myers Squibb Description and Business Overview
 Table 92. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Bristol-Myers Squibb Platinum-based Antineoplastic Product
 Table 94. Bristol-Myers Squibb Recent Developments/Updates
 Table 95. Asta Medica GmbH Company Information
 Table 96. Asta Medica GmbH Description and Business Overview
 Table 97. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Asta Medica GmbH Platinum-based Antineoplastic Product
 Table 99. Asta Medica GmbH Recent Developments/Updates
 Table 100. Simcere Pharmaceutical Company Information
 Table 101. Simcere Pharmaceutical Description and Business Overview
 Table 102. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Simcere Pharmaceutical Platinum-based Antineoplastic Product
 Table 104. Simcere Pharmaceutical Recent Developments/Updates
 Table 105. Abbvie Company Information
 Table 106. Abbvie Description and Business Overview
 Table 107. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Abbvie Platinum-based Antineoplastic Product
 Table 109. Abbvie Recent Developments/Updates
 Table 110. Novartis Company Information
 Table 111. Novartis Description and Business Overview
 Table 112. Novartis Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Novartis Platinum-based Antineoplastic Product
 Table 114. Novartis Recent Developments/Updates
 Table 115. GSK Company Information
 Table 116. GSK Description and Business Overview
 Table 117. GSK Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. GSK Platinum-based Antineoplastic Product
 Table 119. GSK Recent Developments/Updates
 Table 120. MSD Company Information
 Table 121. MSD Description and Business Overview
 Table 122. MSD Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. MSD Platinum-based Antineoplastic Product
 Table 124. MSD Recent Developments/Updates
 Table 125. Hengrui Medicine Company Information
 Table 126. Hengrui Medicine Description and Business Overview
 Table 127. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Hengrui Medicine Platinum-based Antineoplastic Product
 Table 129. Hengrui Medicine Recent Developments/Updates
 Table 130. Hansoh Pharmaceutical Group Company Information
 Table 131. Hansoh Pharmaceutical Group Description and Business Overview
 Table 132. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product
 Table 134. Hansoh Pharmaceutical Group Recent Developments/Updates
 Table 135. ChiTaiTianQing Pharmaceutical Group Company Information
 Table 136. ChiTaiTianQing Pharmaceutical Group Description and Business Overview
 Table 137. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product
 Table 139. ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates
 Table 140. CSPC Pharmaceutical Group Company Information
 Table 141. CSPC Pharmaceutical Group Description and Business Overview
 Table 142. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product
 Table 144. CSPC Pharmaceutical Group Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Platinum-based Antineoplastic Distributors List
 Table 148. Platinum-based Antineoplastic Customers List
 Table 149. Platinum-based Antineoplastic Market Trends
 Table 150. Platinum-based Antineoplastic Market Drivers
 Table 151. Platinum-based Antineoplastic Market Challenges
 Table 152. Platinum-based Antineoplastic Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Platinum-based Antineoplastic
 Figure 2. Global Platinum-based Antineoplastic Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Platinum-based Antineoplastic Market Share by Type: 2024 & 2031
 Figure 4. Cisplatin Product Picture
 Figure 5. Carboplatin Product Picture
 Figure 6. Nedaplatin Product Picture
 Figure 7. Oxaliplatin Product Picture
 Figure 8. Lobaplatin Product Picture
 Figure 9. Cycloplatin Product Picture
 Figure 10. Global Platinum-based Antineoplastic Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Platinum-based Antineoplastic Market Share by Application: 2024 & 2031
 Figure 12. Combination Therapy
 Figure 13. Monotherapy
 Figure 14. Targeted Therapy
 Figure 15. Global Platinum-based Antineoplastic Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Platinum-based Antineoplastic Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Platinum-based Antineoplastic Sales (2020-2031) & (Units)
 Figure 18. Global Platinum-based Antineoplastic Average Price (US$/Unit) & (2020-2031)
 Figure 19. Platinum-based Antineoplastic Report Years Considered
 Figure 20. Platinum-based Antineoplastic Sales Share by Manufacturers in 2024
 Figure 21. Global Platinum-based Antineoplastic Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Platinum-based Antineoplastic Players: Market Share by Revenue in Platinum-based Antineoplastic in 2024
 Figure 23. Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Platinum-based Antineoplastic Sales Market Share by Country (2020-2031)
 Figure 26. North America Platinum-based Antineoplastic Revenue Market Share by Country (2020-2031)
 Figure 27. United States Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Platinum-based Antineoplastic Sales Market Share by Country (2020-2031)
 Figure 30. Europe Platinum-based Antineoplastic Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Platinum-based Antineoplastic Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Platinum-based Antineoplastic Revenue Market Share by Region (2020-2031)
 Figure 38. China Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. China Taiwan Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Southeast Asia Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Platinum-based Antineoplastic Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Platinum-based Antineoplastic Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Platinum-based Antineoplastic Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Platinum-based Antineoplastic Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Platinum-based Antineoplastic Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Platinum-based Antineoplastic by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Platinum-based Antineoplastic by Type (2020-2031)
 Figure 57. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Platinum-based Antineoplastic by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Platinum-based Antineoplastic by Application (2020-2031)
 Figure 60. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2020-2031)
 Figure 61. Platinum-based Antineoplastic Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Cisplatin Injection Market Research Report 2024
Global Anti tumor Drug Market Research Report 2025
Hormone Antineoplastic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Platinum Nitrate Market Research Report 2024
Global Platinum based Cancer Drug Market Insights Forecast to 2030
Global Platinum based Anticancer APIs Market Research Report 2024
Platinum based Anticancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Carboplatin Market Research Report 2025
Antineoplastic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Anti Neoplastic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Neoplastic Therapy Market Research Report 2024
Antineoplastic Interferon Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology and Cancer Treatment Drug Market Research Report 2024
Platinum Anti tumor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cis diiododiammineplatinum Market Research Report 2024
Global Natural Antitumor Drug Market Research Report 2024
Global Platinum Coating Market Research Report 2025
Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nephroblastoma Chemotherapy Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Carboplatin Injection Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions